I wrote an article about Synergy Pharmaceuticals (NASDAQ:SGYP) ("Synergy" or "the company") in November of last year right before the stock made a significant move leading up to Phase 2 IBS-C results. You can refer to my previous article for more info on the company and the product pipeline they are developing.
A few quick highlights on what has occurred since my November 2013 article are as follows:
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|